LYNDSEY DEGENHARDT: Open Payments
NPI 1760623086 · ELKHORN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,269 in 114 payments from 16 companies in 2025. Trend: 2023 $2,474 · 2024 $2,166 · 2025 $2,269
Food & beverage: $2,174Education: $95
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 11 | $294 |
| ABBVIE INC. | 13 | $265 |
| Regeneron Healthcare Solutions, Inc. | 8 | $213 |
| Lilly USA, LLC | 11 | $201 |
| Novartis Pharmaceuticals Corporation | 8 | $195 |
| UCB, Inc. | 9 | $193 |
| GENZYME CORPORATION | 10 | $185 |
| Galderma Laboratories, L.P. | 11 | $148 |
| E.R. Squibb & Sons, L.L.C. | 11 | $144 |
| Incyte Corporation | 5 | $119 |
Products named: TREMFYA, DUPIXENT, SKYRIZI, TALTZ, Bimzelx, COSENTYX, Sotyktu, NEMLUVIO.
Industry payments across NE — which companies pay providers there.
